Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2026-03-10 Investor Presentation
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
DistributeRx Launch Investor Presentation 35 pages 2.3MB
Investor Presentation Classification · 95% confidence The document is titled 'DistributeRX LAUNCH: INVESTOR PRESENTATION' and is dated 11 March 2026. It is an investor presentation by Mayne Pharma Group Limited regarding the US launch of DistributeRx. The content includes company background, financial snapshots, segment contributions, and strategic focus areas. It also mentions a webinar for investors and includes forward-looking statements and non-IFRS financial information. The document is lengthy (15,000 characters) and contains detailed financial and strategic information aimed at investors. There is no indication that this is a full annual or interim report, audit report, earnings release, or regulatory filing. The presence of slides, agenda, and speaker information confirms it is a presentation. Therefore, the document best fits the category of an Investor Presentation (IP).
2026-03-10 English
Mayne Pharma launches DistributeRx in the US 4 pages 228.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Mayne Pharma Group Limited about the launch of a new healthcare solutions business called DistributeRx in the US. It details the business model, strategic priorities, and includes information about an upcoming investor webinar. The content focuses on a business update and strategic initiative rather than financial results, regulatory filings, or management changes. It does not contain financial statements or detailed financial data, nor is it a transcript of a call or a report publication announcement. The document is a corporate announcement about a new business launch and strategic direction, which fits best under Capital/Financing Update (CAP) as it relates to business expansion and strategic growth initiatives that impact capital structure and shareholder value.
2026-03-09 English
Becoming a substantial holder 5 pages 264.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 under the Corporations Act Section 671B, titled 'Notice of initial substantial shareholder.' It details the substantial shareholding of Citigroup Global Markets Australia Pty Limited in Mayne Pharma Group Ltd, including voting power, relevant interests, registered holders, consideration paid, and associates. The document is a regulatory disclosure about a change in significant share ownership, specifically notifying the market and regulators about a substantial shareholder crossing a threshold. It does not contain financial statements, management discussion, or other report content. This type of filing corresponds to a Major Shareholding Notification (MRQ). The document length is 7,389 characters, which is consistent with a detailed notification rather than a full report or announcement of a report publication. Therefore, the correct classification is MRQ with high confidence.
2026-03-08 English
Becoming a substantial holder 5 pages 318.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 under the Corporations Act 2001 Section 671B, titled 'Notice of initial substantial holder'. It details the substantial shareholding interests and voting power of various entities in Mayne Pharma Group Limited, including acquisition dates, consideration paid, and relevant interests. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is lengthy and contains detailed transaction data, confirming it is the actual notification rather than a brief announcement or certification. Therefore, the correct classification is MRQ.
2026-03-02 English
Final Director's Interest Notice (x2) 4 pages 583.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the interests of directors in securities, including registered and non-registered holdings, and notes the cessation dates of directors. This type of document is a formal notification of personal share transactions or holdings by company directors. It is not a financial report, earnings release, or management discussion. The content aligns with the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure of director interests in securities.
2026-03-01 English
Ceasing to be a substantial holder from MUFG 16 pages 557.0KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605' and is described as a 'Notice of ceasing to be a substantial holder' under the Corporations Act 2001 Section 671B. It details changes in relevant interests and associations of a substantial holder, Mitsubishi UFJ Financial Group, Inc., including dates and numbers of securities affected. The document is a regulatory notice about shareholding changes rather than a financial report, earnings release, or management discussion. It does not contain financial statements or management commentary but focuses on shareholding disclosures. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2026-03-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.